Where can I get one of those crystal balls?
A few years ago I believed UBS information on the future price direction of 3 well established businesses, should have backed myself. Clearly they have no crystal balls there.
I think the issue here is the beginning of a new medical paradigm. Not subject to quite the same restrictions as, for instance, an A2 milk producer.
The US government see cellular and genetic medicine as worth encouraging, in the past year or so they have lowered the bar in terms of providing accelerated bureaucratic pathways to speed things up. At least one larger pharmaceutical businesses would like to buy in, Takeeda, announced their offer for TiGenix just a few weeks after MSB agreed to license the target businesses primary product for one particular use.
On a different tack I'm curious optimistus, which business before they are profitable does not have to acknowledge risks in their reports? Will they still have to acknowledge risks after profitability is reached?
Mesoblast's Delayed Launches, Teva Split Turn Credit Suisse Bearish, page-30
Add to My Watchlist
What is My Watchlist?
